-transparent.png){kind=logo}
A series of indole derivatives with varied substituents on the alpha, beta-unsaturated double bond were synthesized and evaluated for their ability to inhibit rat prostatic 5 alpha-reductase. Compounds possessing an ethyl substituent at the beta-position of the double bond showed potent inhibitory activity. Among them, (Z)-4-{2-[[3-[1-(4,4'-difluorobenzhydryl)indol-5-yl]-2-pentenoy l]- amino]phenoxy}butyric acid (16, KF20405) showed the maximum potency with an IC50 value of 0.48 +/- 0.086 nM, which was 20-fold higher potency than 1 (MK-906). Compound 16 effectively inhibited DHT production 4 h after a 3 mg/kg oral administration. Several potent indole derivatives, 1 and 2 ((+/-)-ONO-3805), were tested versus rat and human isozymes. Nonsteroidal inhibitors such as indole derivatives and 2 were 2-3 orders of magnitude less potent for human type 2 isozyme than steroidal inhibitor 1 and expressed a significant species deference for these isozymes.
H Takami, and
H Koshimura, and
N Kishibayashi, and
A Ishii, and
H Nonaka, and
S Aoyama, and
H Kase, and
T Kumazawa
November 1997,
Chemical & pharmaceutical bulletin,
H Takami, and
H Koshimura, and
N Kishibayashi, and
A Ishii, and
H Nonaka, and
S Aoyama, and
H Kase, and
T Kumazawa
August 1999,
Chemical & pharmaceutical bulletin,
H Takami, and
H Koshimura, and
N Kishibayashi, and
A Ishii, and
H Nonaka, and
S Aoyama, and
H Kase, and
T Kumazawa
March 1990,
Journal of medicinal chemistry,
H Takami, and
H Koshimura, and
N Kishibayashi, and
A Ishii, and
H Nonaka, and
S Aoyama, and
H Kase, and
T Kumazawa
December 1998,
Bioorganic & medicinal chemistry,
H Takami, and
H Koshimura, and
N Kishibayashi, and
A Ishii, and
H Nonaka, and
S Aoyama, and
H Kase, and
T Kumazawa
March 2000,
Chemical & pharmaceutical bulletin,
H Takami, and
H Koshimura, and
N Kishibayashi, and
A Ishii, and
H Nonaka, and
S Aoyama, and
H Kase, and
T Kumazawa
January 2019,
Assay and drug development technologies,
H Takami, and
H Koshimura, and
N Kishibayashi, and
A Ishii, and
H Nonaka, and
S Aoyama, and
H Kase, and
T Kumazawa
April 2015,
Molecules (Basel, Switzerland),
H Takami, and
H Koshimura, and
N Kishibayashi, and
A Ishii, and
H Nonaka, and
S Aoyama, and
H Kase, and
T Kumazawa
January 2003,
Current opinion in urology,
H Takami, and
H Koshimura, and
N Kishibayashi, and
A Ishii, and
H Nonaka, and
S Aoyama, and
H Kase, and
T Kumazawa
January 2017,
European journal of medicinal chemistry,
H Takami, and
H Koshimura, and
N Kishibayashi, and
A Ishii, and
H Nonaka, and
S Aoyama, and
H Kase, and
T Kumazawa
October 2023,
RSC advances,
